BEAD-BASED ASSAY FOR SIMULTANEOUS DETECTION OF BIOMOLECULES
The present disclosure provides methods for determining the presence of at least one biomolecule in a sample. The present disclosure further provides methods for determining the presence of a coronavirus antibody in a sample.
1 . A method for determining the presence of at least one biomolecule in a sample comprising:
(a) obtaining a sample from a subject;
(b) incubating the sample with a composition comprising a first bead, wherein said first bead is conjugated with (i) a first barcode moiety, (ii) a second barcode moiety, and (iii) a ligand capable of binding to the biomolecule, thereby producing a composition comprising a first construct, wherein said first construct comprises the first bead, the ligand and the biomolecule;
(c) incubating the composition of (b) with a composition comprising a second bead, wherein said second bead is conjugated with an agent capable of binding to the biomolecule of the first construct, thereby producing a composition comprising a second construct, wherein said second construct comprises the first bead, the ligand, the biomolecule, the agent, and the second bead;
(d) washing the composition of (c) under conditions that allow removal of unbound beads;
(e) separating the first bead from the second bead under conditions that allow detection of the first bead comprising the first barcode moiety and the second barcode moiety; and
(f) determining the presence of the first barcode moiety and the second barcode moiety.
2 . The method of claim 1 , wherein the subject is an animal, plant, fungi, protist, bacterium or archaea.
3 . The method of claim 2 , wherein the animal is human.
4 . The method of claim 1 , wherein the presence of 2, 3, 4, 5 or more biomolecules are determined.
5 . The method of claim 1 , wherein the sample is a blood, serum, saliva, nasal/oropharyngeal swab, semen, urine, lymph, cerebrospinal fluid, interstitial fluid, spinal fluid, peritoneal fluid, pleural fluid, amniotic fluid, stool, bile, bone marrow, or skin sample.
6 . The method of claim 1 , wherein the first barcode moiety identifies the subject.
7 . The method of claim 1 , wherein the second barcode moiety identifies the ligand.
8 . The method of claim 1 , wherein the biomolecule is an antibody, protein or a nucleic acid.
9 . The method of claim 8 , wherein the nucleic acid is an RNA.
10 . The method of claim 8 , wherein the nucleic acid is a DNA.
11 . The method of claim 9 , wherein the RNA is RNA from a pathogen.
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . The method of claim 1 , wherein the agent is an antibody, protein or nucleic acid which binds to the biomolecule.
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . A method for determining the presence of a coronavirus antibody in a sample comprising:
(a) obtaining a blood sample from a human subject;
(b) incubating the sample with a composition comprising a first bead, wherein said first bead is conjugated with (i) a first barcode moiety comprising a first isotope or a first combination of isotopes, (ii) a second barcode moiety comprising a second isotope or a second combination of isotopes, and (iii) a ligand comprising a coronavirus spike or nucleocapsid protein or fragment thereof capable of binding to the coronavirus antibody, thereby producing a composition comprising a first construct, wherein said first construct comprises the first bead, the ligand and the coronavirus antibody;
(c) incubating the composition of (b) with a composition comprising a second bead, wherein said second bead is conjugated with an agent comprising an anti-human immunoglobulin antibody capable of binding to the coronavirus antibody of the first construct, thereby producing a composition comprising a second construct, wherein said second construct comprises the first bead, the ligand, the coronavirus antibody, the agent, and the second bead;
(d) washing the composition of (c) under conditions that allow removal of unbound beads;
(e) separating the first bead from the second bead under conditions that allow detection of the first bead comprising the first barcode moiety and the second barcode moiety; and
(f) determining the presence of the first barcode moiety and the second barcode moiety.
23 . The method of claim 22 , wherein the coronavirus antibody is an anti-Spike protein antibody for SARS-COV-1 or SARS-COV-2.
24 . (canceled)
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . A method for determining the presence of at least one biomolecule in a sample comprising:
(a) obtaining a sample from a subject;
(b) incubating the sample with a composition comprising a plurality of ligand beads, wherein each ligand bead is conjugated with (i) a first barcode moiety that is unique for each sample, (ii) a second barcode moiety that is unique for each associated ligand, and (iii) a ligand capable of binding to the biomolecule, thereby producing a composition comprising a first construct, wherein said first construct comprises the first bead, the ligand and the biomolecule;
(c) incubating the composition of (b) with a composition comprising a plurality of detection beads, wherein each detection bead is conjugated with an agent capable of binding to the biomolecule of the first construct, thereby producing a composition comprising a second construct, wherein said second construct comprises the first bead, the ligand, the biomolecule, the agent, and the second bead;
(d) washing the composition of (c) under conditions that allow removal of unbound beads;
(e) separating the first bead from the second bead under conditions that allow detection of the first bead comprising the first barcode moiety and the second barcode moiety; and
(f) determining the presence of the first barcode moiety and the second barcode moiety.
29 . The method of claim 28 , wherein the presence of a signal from the second barcode moiety is indicative of a current or prior infection from a pathogen associated with the ligand.
30 .- 35 . (canceled)